Welcome to our dedicated page for LeonaBio SEC filings (Ticker: ATHA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on LeonaBio's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into LeonaBio's regulatory disclosures and financial reporting.
Athira Pharma (ATHA) filed its Q3 2025 10‑Q reporting narrower losses and a streamlined cost base. Net loss was $6.6 million for the quarter, a sharp improvement from $28.7 million a year ago, as research and development and general and administrative expenses declined. Other income contributed modestly.
Cash, cash equivalents and investments were $25.2 million as of September 30, 2025. Management states this balance is sufficient to fund operating expenses and capital needs for at least the next 12 months, and the company maintains a $75.0 million at‑the‑market equity facility with Cantor Fitzgerald and BTIG, with no sales to date.
The company effected a 1‑for‑10 reverse stock split on September 17, 2025 and subsequently regained Nasdaq minimum bid compliance on October 2, 2025. Athira has paused fosgonimeton development and is focusing on ATH‑1105 for ALS; a completed Phase 1 in healthy volunteers showed a favorable safety profile. Shares outstanding were 3,943,887 as of November 5, 2025.
Athira Pharma (ATHA) furnished an 8-K stating it issued a press release reporting financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1.
The company notes that information under Items 2.02 and 7.01, and Exhibit 99.1, is furnished and not deemed filed under the Exchange Act. Athira also highlights its disclosure channels, including its website, investor site, and social media accounts on X (@athirapharma), LinkedIn, Instagram (@athirapharma), and Facebook.
A Schedule 13G/A reports that Steven Michael Oliveira and affiliated entities collectively disclose 161,218 shares of Athira Pharma common stock, representing 4.088% of the class. Nemean Asset Management, LLC is shown with 151,218 shares (3.834%) and South Ocean Capital LLC with 10,000 shares (0.253%), all filed from a common address in Jupiter, Florida. The filing states the holdings are shared voting and dispositive power and affirms the securities were not acquired to change or influence control of the issuer. Signatures show Oliveira as individual filer and authorized signer for the entities.
Athira Pharma, Inc. reported that it has regained compliance with Nasdaq’s minimum bid price listing rule. The company previously received a notice on October 16, 2024 that its common stock had closed below $1.00 per share for 30 consecutive business days, triggering a deficiency under Nasdaq’s minimum bid requirement.
Nasdaq has now informed Athira that the closing bid price of its common stock was at least $1.00 per share for ten consecutive business days as of October 2, 2025. As a result, Athira is again in compliance with the minimum bid rule and Nasdaq has closed the deficiency matter.
Athira Pharma, Inc. is implementing a 10-for-1 reverse stock split of its common stock, effective as of 5:00 p.m. Eastern Time on September 17, 2025. This means every ten existing shares will be combined into one share, while the par value per share remains $0.0001.
The company is also reducing its authorized common stock from 900,000,000 to 90,000,000 shares and total authorized capital stock from 1,000,000,000 to 190,000,000 shares. Athira’s common stock is expected to begin trading on a post-split basis on The Nasdaq Capital Market on September 18, 2025 under the symbol ATHA.
Fractional shares resulting from the reverse split will be settled in cash, and proportional adjustments will be made to outstanding options, restricted stock units, and equity plan reserves. Stockholders holding shares in book-entry or through brokers will have their holdings automatically adjusted without needing to take action.